Nektar Therapeutics
NASDAQ:NKTR

Watchlist Manager
Nektar Therapeutics Logo
Nektar Therapeutics
NASDAQ:NKTR
Watchlist
Price: 1.205 USD -5.86% Market Closed
Market Cap: 221.8m USD
Have any thoughts about
Nektar Therapeutics?
Write Note

Intrinsic Value

NKTR's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one NKTR stock under the Base Case scenario is 0.692 USD. Compared to the current market price of 1.205 USD, Nektar Therapeutics is Overvalued by 43%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

NKTR Intrinsic Value
0.692 USD
Overvaluation 43%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Nektar Therapeutics

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for NKTR cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about NKTR?
Bearish
Neutral
Bullish

Fundamental Analysis

Risks & Rewards

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Notes
AI Assistant
AI Assistant
Ask me anything about Nektar Therapeutics

Provide an overview of the primary business activities
of Nektar Therapeutics.

What unique competitive advantages
does Nektar Therapeutics hold over its rivals?

What risks and challenges
does Nektar Therapeutics face in the near future?

Summarize the latest earnings call
of Nektar Therapeutics.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Nektar Therapeutics.

Provide P/S
for Nektar Therapeutics.

Provide P/E
for Nektar Therapeutics.

Provide P/OCF
for Nektar Therapeutics.

Provide P/FCFE
for Nektar Therapeutics.

Provide P/B
for Nektar Therapeutics.

Provide EV/S
for Nektar Therapeutics.

Provide EV/GP
for Nektar Therapeutics.

Provide EV/EBITDA
for Nektar Therapeutics.

Provide EV/EBIT
for Nektar Therapeutics.

Provide EV/OCF
for Nektar Therapeutics.

Provide EV/FCFF
for Nektar Therapeutics.

Provide EV/IC
for Nektar Therapeutics.

Show me price targets
for Nektar Therapeutics made by professional analysts.

What are the Revenue projections
for Nektar Therapeutics?

How accurate were the past Revenue estimates
for Nektar Therapeutics?

What are the Net Income projections
for Nektar Therapeutics?

How accurate were the past Net Income estimates
for Nektar Therapeutics?

What are the EPS projections
for Nektar Therapeutics?

How accurate were the past EPS estimates
for Nektar Therapeutics?

What are the EBIT projections
for Nektar Therapeutics?

How accurate were the past EBIT estimates
for Nektar Therapeutics?

Compare the revenue forecasts
for Nektar Therapeutics with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Nektar Therapeutics and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Nektar Therapeutics against its competitors.

Analyze the profit margins
(gross, operating, and net) of Nektar Therapeutics compared to its peers.

Compare the P/E ratios
of Nektar Therapeutics against its peers.

Discuss the investment returns and shareholder value creation
comparing Nektar Therapeutics with its peers.

Analyze the financial leverage
of Nektar Therapeutics compared to its main competitors.

Show all profitability ratios
for Nektar Therapeutics.

Provide ROE
for Nektar Therapeutics.

Provide ROA
for Nektar Therapeutics.

Provide ROIC
for Nektar Therapeutics.

Provide ROCE
for Nektar Therapeutics.

Provide Gross Margin
for Nektar Therapeutics.

Provide Operating Margin
for Nektar Therapeutics.

Provide Net Margin
for Nektar Therapeutics.

Provide FCF Margin
for Nektar Therapeutics.

Show all solvency ratios
for Nektar Therapeutics.

Provide D/E Ratio
for Nektar Therapeutics.

Provide D/A Ratio
for Nektar Therapeutics.

Provide Interest Coverage Ratio
for Nektar Therapeutics.

Provide Altman Z-Score Ratio
for Nektar Therapeutics.

Provide Quick Ratio
for Nektar Therapeutics.

Provide Current Ratio
for Nektar Therapeutics.

Provide Cash Ratio
for Nektar Therapeutics.

What is the historical Revenue growth
over the last 5 years for Nektar Therapeutics?

What is the historical Net Income growth
over the last 5 years for Nektar Therapeutics?

What is the current Free Cash Flow
of Nektar Therapeutics?

Discuss the annual earnings per share (EPS)
trend over the past five years for Nektar Therapeutics.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Nektar Therapeutics

Current Assets 295.2m
Cash & Short-Term Investments 271.2m
Receivables 1.2m
Other Current Assets 22.8m
Non-Current Assets 48.1m
Long-Term Investments 19.4m
PP&E 24.4m
Other Non-Current Assets 4.3m
Current Liabilities 57.3m
Accounts Payable 6.5m
Accrued Liabilities 50.9m
Non-Current Liabilities 206.3m
Other Non-Current Liabilities 206.3m
Efficiency

Earnings Waterfall
Nektar Therapeutics

Revenue
93.1m USD
Cost of Revenue
-38m USD
Gross Profit
55.2m USD
Operating Expenses
-190.3m USD
Operating Income
-135.1m USD
Other Expenses
-41.9m USD
Net Income
-177m USD

Free Cash Flow Analysis
Nektar Therapeutics

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

NKTR Profitability Score
Profitability Due Diligence

Nektar Therapeutics's profitability score is 19/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Positive 1-Year Revenue Growth
Negative Revenue Growth Forecast
Negative 3-Years Revenue Growth
19/100
Profitability
Score

Nektar Therapeutics's profitability score is 19/100. The higher the profitability score, the more profitable the company is.

NKTR Solvency Score
Solvency Due Diligence

Nektar Therapeutics's solvency score is 54/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Low D/E
Long-Term Solvency
Low Altman Z-Score
54/100
Solvency
Score

Nektar Therapeutics's solvency score is 54/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

NKTR Price Targets Summary
Nektar Therapeutics

Wall Street analysts forecast NKTR stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for NKTR is 2.703 USD with a low forecast of 1.313 USD and a high forecast of 4.2 USD.

Lowest
Price Target
1.313 USD
9% Upside
Average
Price Target
2.703 USD
124% Upside
Highest
Price Target
4.2 USD
249% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for NKTR?

Click here to dive deeper.

Dividends

Nektar Therapeutics
does not pay dividends
Shareholder Yield

Current shareholder yield for NKTR is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

NKTR News

Profile

Nektar Therapeutics Logo
Nektar Therapeutics

Country

United States of America

Industry

Pharmaceuticals

Market Cap

221.8m USD

Dividend Yield

0%

Description

Nektar Therapeutics is a research-based biopharmaceutical company which engages in discovering and developing medicines in areas of unmet medical need. The company is headquartered in San Francisco, California and currently employs 740 full-time employees. The firm's research and development pipeline of new investigational drugs includes potential therapies for oncology, immunology and virology. In oncology, it is studying several immuno-oncology (I-O) drug candidates, including bempegaldesleukin, NKTR-255 and NKTR-262. In immunology, it is focused on addressing imbalances in the immune system to restore the body's self-tolerance mechanisms and achieve immune homeostasis. In autoimmune disorders, its IL-2 T-regulatory cell stimulator NKTR-358 is being clinically studied in systemic lupus erythematosus, ulcerative colitis, psoriasis and atopic dermatitis. Its programs in virology area include studying bempegaldesleukin in treating individuals affected with COVID-19, and a preclinical research collaboration with Gilead Sciences Inc. (Gilead) to test the combination of NKTR-255.

Contact

CALIFORNIA
San Francisco
455 Mission Bay Blvd S
+14154825300.0
www.nektar.com

IPO

1994-05-03

Employees

740

Officers

CEO, President & Director
Mr. Howard W. Robin
Chief Financial Officer
Ms. Sandra A. Gardiner
Senior VP, Chief Legal Officer & Secretary
Mr. Mark A. Wilson
Chief Research & Development Officer
Dr. Jonathan Zalevsky Ph.D.
Director of Investor Relations & Corporate Affairs
Vivian Wu
Senior Vice President of Human Resources & Facilities Operations
Mr. Robert Bacci
Show More
Chief Business Officer
Ms. Jennifer Ruddock
Chief Medical Officer
Dr. Mary Tagliaferri L.Ac., M.D.
Show Less

See Also

Discover More
What is the Intrinsic Value of one NKTR stock?

The intrinsic value of one NKTR stock under the Base Case scenario is 0.692 USD.

Is NKTR stock undervalued or overvalued?

Compared to the current market price of 1.205 USD, Nektar Therapeutics is Overvalued by 43%.

Back to Top